Oesophageal cancer, malignant (ICD10 C15): combined sexes

One-year and five-year relative survival by diagnosis year and age at diagnosis

	One-year relative survival (with 95% confidence interval) by diagnosis year				EUROCARE-4	EUROCARE-4
Age at diagnosis	1994-97	1998-2002	2003-2007	2007-2009	##1995-1999	##1995-1999
	cohort	cohort	cohort	*hybrid	Ireland	Europe average

all 15-99	27.5%	33.0%	39.8%	40.6%
(unstandardized)	(24.8-30.1%)	(30.5-35.5%)	(37.3-42.2%)	(37.6-43.5%)

all 15-99	29.7%	35.0%	41.5%	43.2%	32.7%	35.8%
(age-standardized)#	(23.4-35.9%)	(29.3-40.5%)	(35.8-46.9%)	(35.9-50%)	(30.1-35.4%)	(35.0-36.5%)

15-44	48.7%	59.0%	55.4%	54.8%
	(31.4-63.8%)	(45.0-70.5%)	(40.1-68.2%)	(36.9-69.6%)

45-54	37.8%	48.8%	54.2%	53.4%
	(28.7-46.8%)	(40.3-56.6%)	(46.2-61.5%)	(42.9-62.7%)

55-64	37.4%	39.4%	50.6%	53.4%
	(30.5-44.2%)	(33.3-45.2%)	(45.0-55.8%)	(46.3-59.9%)

65-74	26.7%	33.5%	38.1%	41.6%
	(22.1-31.3%)	(28.9-38.0%)	(33.6-42.6%)	(35.5-47.5%)

75-99	18.8%	21.6%	29.1%	29.7%
	(15.1-22.8%)	(18.0-25.4%)	(25.3-33.0%)	(24.9-34.6%)

	Five-year relative survival (with 95% confidence interval) by diagnosis year				EUROCARE-4	EUROCARE-4
Age at diagnosis	1994-97	1998-2002	2003-2007	2005-2008	##1995-1999	##1995-1999
	cohort	cohort	cohort	*hybrid	Ireland	Europe average

all 15-99	12.5%	13.1%	15.8%	14.9%
(unstandardized)	(10.3-14.8%)	(11.1-15.1%)	(13.3-18.6%)	(12.3-17.6%)

all 15-99	12.9%	13.2%	16.2%	15.5%	12.6%	11.1%
(age-standardized)#	(8.4-18.4%)	(9.1-18.0%)	(10.9-22.4%)	(10.0-22.0%)	(10.7-14.9%)	(10.5-11.6%)

15-44	20.1%	23.4%	29.3%	27.0%
	(8.9-34.7%)	(13.3-35.1%)	(17.0-42.7%)	(13.8-42.0%)

45-54	17.9%	19.9%	18.1%	16.9%
	(11.2-25.7%)	(13.7-26.8%)	(10.7-27.0%)	(9.9-25.4%)

55-64	19.3%	15.0%	21.1%	21.0%
	(13.9-25.4%)	(10.8-19.8%)	(15.7-26.9%)	(15.2-27.5%)

65-74	8.5%	11.4%	12.6%	11.8%
	(5.7-12.0%)	(8.4-14.9%)	(8.7-17.2%)	(7.9-16.5%)

75-99	8.3%	8.4%	12.0%	11.3%
	(5.3-12.1%)	(5.6-11.9%)	(7.9-17.2%)	(7.1-16.7%)

Footnotes:

*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period,

supplemented by follow-up 2005-2009 for cases diagnosed in 2005 or 2006 (to provide more reliable estimation of the first two years of survival).

In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data.

# Age-standardized figures use the standard patient population proposed for this cancer by:

Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316.

(Population weights = age 15-44 x7000, 45-54 x12000, 55-64 x23000, 65-74 x29000, 75-99 x29000)

## For comparison, the age-standardized average survival is quoted for countries (including Ireland) that participated in the EUROCARE-4 study:

Sant M. et al. 2009. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45: 931-991.

Exclusions (as in EUROCARE):

Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient

(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour.